CompletedPhase 2NCT00718692
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Symphogen A/S
- Principal Investigator
- Mario Von Depka Prondzinski, PD Dr.Werlhoff Institut Hannover, Germany
- Intervention
- Sym001(drug)
- Enrollment
- 61 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2011
Study locations (30)
- Univ Nebraska Med Ctr. UNMC, 1005, Omaha, Nebraska, United States
- Hospital of the University of Pennsylvania, Site 1002, Philadelphia, Pennsylvania, United States
- 2085 Henry Tecklenburg Drive, 1001, Charleston, South Carolina, United States
- Research Site 3203, Bruges, Belgium
- Research Site 3202, Leuven, Belgium
- Research Site 3201, Yvoir, Belgium
- Research Site 4906, 4907, Berlin, Germany
- Research Site 4902, Cologne, Germany
- Research Site 4903, Duisburg, Germany
- Research Site 4905, Essen, Germany
- Reseach Site 4908, Halle, Germany
- Research Site 4901, Hanover, Germany
- Research Site 4904, Regensburg, Germany
- St. John's Medical College Hospital, 9106, Bangalore, India
- MS Ramaiah Memorial Hospital, 9108, Bangalore, India
- +15 more locations on ClinicalTrials.gov
Collaborators
Swedish Orphan Biovitrum
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00718692 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation